Announced Tue, 14 Jul · 10:47 IST
Ipca Labs BRSR FY26: 13.5% emission cut, 42% exports, zero bribery cases
Compliance View source PDF
IPCALAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.2%1-day move
₹1824.90
prior close
₹1824.50
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.1+0.2+0.0+0.1+2.2+3.2+6.3+0.3-1.6-2.9————
Up moveDown movePending
AI summary
Ipca Labs filed its BRSR for FY25-26 covering standalone operations. Pharma company with Rs 7,431 Cr turnover and Rs 7,979 Cr net worth, with 42% revenue from exports to 100-plus countries. Cut Scope 1 and 2 emissions intensity 13.5% versus 2024 baseline and achieved 50.8% hazardous waste co-processing diversion. Workforce of 16,052 permanent employees with 20.59% women in offices. Zero bribery or corruption cases. BRSR assured by SGS India.
Likely market impact
Routine annual ESG disclosure. Shows progress on emission and diversity targets with zero corruption incidents. No direct share price impact expected.